Drug Profile


Alternative Names: NDV-3; NDV-3A

Latest Information Update: 02 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LA BioMed; NovaDigm Therapeutics
  • Developer National Institute of Allergy and Infectious Diseases; NovaDigm Therapeutics
  • Class Antibacterials; Antifungals; Bacterial vaccines; Fungal vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Candidiasis; Staphylococcal infections
  • Phase I/II Vulvovaginal candidiasis
  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 25 Apr 2018 Updated efficacy and adverse events data from a phase IIa trial in Vulvovaginal candidiasis released by NovaDigm Therapeutics
  • 19 Apr 2018 NovaDigm Therapeutics initiates enrolment in a phase IIa trial for Staphylococcus infections (Prevention) in USA
  • 30 Jan 2018 NovaDigm Therapeutics initiates a phase IIa trial for Staphylococcal infections (Prevention) in USA (NCT03455309)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top